UnitedHealth Group Incorporated

UnitedHealth Group Incorporated (UNH) Market Cap

UnitedHealth Group Incorporated has a market capitalization of $314.06B.

Financials based on reported quarter end 2025-12-31

Price: $346.01

β–² 22.53 (6.96%)

Market Cap: 314.06B

NYSE Β· time unavailable

CEO: Stephen J. Hemsley

Sector: Healthcare

Industry: Medical - Healthcare Plans

IPO Date: 1984-10-17

Website: https://www.unitedhealthgroup.com

UnitedHealth Group Incorporated (UNH) - Company Information

Market Cap: 314.06B Β· Sector: Healthcare

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage and well-being services to individuals age 50 and older addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance and health care programs; health and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.

Analyst Sentiment

74%
Strong Buy

Based on 52 ratings

Analyst 1Y Forecast: $382.11

Average target (based on 5 sources)

Consensus Price Target

Low

$327

Median

$374

High

$444

Average

$378

Potential Upside: 9.3%

Price & Moving Averages

Loading chart...

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ UnitedHealth Group Incorporated (UNH) β€” Investment Overview

🧩 Business Model Overview

UnitedHealth Group is a leading diversified health care company, operating through two primary platforms: UnitedHealthcare, which provides health benefit plans and services, and Optum, which offers information and technology-enabled health services. The company serves a broad spectrum of customers, including individuals, employers, governments, and health care providers. UnitedHealth Group’s operations span across various segments such as commercial, government, and international markets, delivering a comprehensive suite of healthcare solutions and managed care services.

πŸ’° Revenue Model & Ecosystem

UNH generates income from multiple interconnected sources. Its largest revenue stream originates from insurance premiums paid by individuals, employers, and government-sponsored programs, which form the backbone of its UnitedHealthcare business. Complementing this are the extensive service-based revenues from Optum, which provides pharmacy benefit management, healthcare analytics, technology solutions, and direct care services. The ecosystem is designed to foster collaboration among payers, providers, and patients, leveraging scale and data to promote better outcomes and operational efficiency. UNH serves both enterprise clients, such as large employers and government agencies, and direct-to-consumer channels within its core and adjacent markets.

🧠 Competitive Advantages

  • Brand strength: UnitedHealth Group is recognized as a trusted industry leader in healthcare and insurance, benefiting from longstanding customer relationships and credibility.
  • Switching costs: The complexity of healthcare benefits, coupled with the integration of several services (medical, pharmacy, and care delivery), raises switching costs for both institutional clients and individual members.
  • Ecosystem stickiness: Deep integration of analytics, technology, care management, and distribution channels creates an interdependent ecosystem that is difficult for competitors or customers to replicate or leave.
  • Scale + supply chain leverage: UNH’s size enables it to negotiate favorable terms with providers, suppliers, and technology vendors, enhancing its cost advantages and purchasing power across its platforms.

πŸš€ Growth Drivers Ahead

Key growth catalysts for UnitedHealth Group include the ongoing expansion of value-based care models, increased outsourcing of health plan administration and technology by third parties, and Optum’s continued growth in data analytics and pharmacy benefits management. The company is strategically positioned to benefit from demographic trends such as an aging population and rising demand for managed Medicaid and Medicare solutions. Further, digital health innovation and investment in personalized care delivery offer new avenues for both organic and acquisitive expansion domestically and internationally.

⚠ Risk Factors to Monitor

Investors should monitor several risks, including intense competition from other managed care organizations and technology-driven entrants. The highly regulated healthcare landscape subjects the company to political and policy risks, including potential changes to reimbursement models and health coverage mandates. Margin pressures from cost inflation, adverse selection, and potential reductions in government funding are also notable. Technological disruption and cybersecurity threats could impact various aspects of operations and data integrity.

πŸ“Š Valuation Perspective

The market generally assigns UnitedHealth Group a valuation premium relative to many peers within the healthcare and insurance sectors. This reflects its diversified revenue model, strong market share, robust growth prospects, and history of operational execution. Investors often view UNH as a bellwether in managed care with attractive defensive characteristics, although premium pricing may imply higher expectations and sensitivity to execution risks or macroeconomic headwinds compared to industry averages.

πŸ” Investment Takeaway

UnitedHealth Group offers a compelling combination of scale, diversification, and innovation within the integrated health services landscape. The long-term bull case is anchored by structural growth drivers, a formidable ecosystem, and the ability to navigate an evolving healthcare environment. However, risks from regulatory changes, margin compression, and emerging competition warrant careful monitoring. Overall, UNH represents a strategic core holding for investors seeking exposure to healthcare, balanced by the need to remain vigilant to sector-specific uncertainties and valuation considerations.


⚠ AI-generated research summary β€” not financial advice. Validate using official filings & independent analysis.

Fundamentals Overview

Loading fundamentals overview...

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"UNH (latest: 2026-03-31) reported Revenue of $111.7B and Net Income of $6.28B, with EPS of $6.90. On a YoY basis, Revenue grew ~+2.0% (from $109.6B in 2025-03-31) while Net Income was roughly flat at -0.2% (from $6.29B). QoQ, Revenue declined ~-1.3% (from $113.2B in 2025-12-31), but Net Income swung sharply upward because 2025-12-31 net income was unusually low. Net margin improved materially in the latest quarter (about 5.6%) versus the prior quarter (~0.0%), after being lower through mid-2025 (near ~2–3%). Cash flow and buybacks aren’t fully disclosed here, but share count is modestly lower vs a year ago (918M β†’ 910M), indicating ongoing capital return. The dividend remains present but yield is low (~0.8%), so total shareholder returns are dominated by price action: the stock is down ~-44.5% over the last year, implying weak total return despite buyback support. Balance sheet resilience appears stable with equity around ~$105B and assets broadly steady (~$309–315B range). Valuation looks comparatively inexpensive (latest P/E ~9.8) relative to the consensus target (~$378), suggesting potential upside if operating earnings normalize."

Revenue Growth

Neutral

QoQ Revenue fell ~-1.3% (111.7B vs 113.2B). YoY Revenue rose ~+2.0% (109.6B β†’ 111.7B), showing modest growth without strong acceleration.

Profitability

Fair

Net margin recovered in the latest quarter (β‰ˆ5.6%) after a very weak prior quarter. Over the 4-quarter span, profitability was volatile (net margin roughly ~5.7% in 2025-03-31, ~2.1% in 2025-09-30, ~3.1% in 2025-06-30, then back to ~5.6%), indicating uneven earnings quality/normalization.

Cash Flow Quality

Fair

Net income is positive and EPS is stable YoY (~$6.90 vs $6.91). Dividend yield is low (~0.8%) but payout ratio appears reasonable in most quarters; however, cash flow details and true dividend coverage/FCF durability are not provided. Buybacks are suggested by a small share count decline.

Leverage & Balance Sheet

Positive

Balance sheet looks resilient: total equity is relatively stable (~$102B–$106B) and total assets remain in a tight range (~$308B–$315B). Net debt trends are broadly steady (~$50B–$54B range).

Shareholder Returns

Neutral

Total return has been weak: the stock is down ~-44.5% over the last year. Dividend yield is low (~0.8%), and share count reduction appears modest, so capital appreciation has dominated and remained negative.

Analyst Sentiment & Valuation

Positive

Consensus target (~$378.1) versus current price (~$324.6) implies ~+16% upside. Latest reported P/E (~9.8) also suggests valuation support, though earnings volatility warrants caution.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

UNH delivered slightly better-than-expected 2025 results with strong cash flow, while taking a largely non-cash $1.6B charge to reset the portfolio and drive execution. 2026 guidance calls for adjusted EPS growth of at least 8.6% with margin expansion at UHC and modest improvements across Optum, but revenue is guided down amid deliberate repricing, portfolio exits, and sizable membership contractionβ€”especially in Medicare Advantage. Management is focused on operational discipline, AI-enabled efficiencies, and value-based care, while acknowledging significant headwinds from funding cuts, elevated medical trends, and competitive dynamics, leading to a cautious near-term outlook with improving momentum expected into 2027.

Growth

  • 2025 revenue up 12% y/y to nearly $448B
  • 2025 adjusted EPS $16.35, slightly above expectations
  • 2026 adjusted EPS outlook >$17.75 (β‰₯8.6% growth); GAAP EPS β‰₯$17.10
  • UnitedHealthcare expected to deliver ~13% adjusted operating earnings growth in 2026 with ~40 bps margin expansion
  • Optum segments targeting low to high single-digit adjusted earnings growth in 2026; margin expansion of 20–90 bps (Rx +20 bps, Insight +90 bps, Health +30 bps)
  • Domestic membership grew >415k in 2025

Business Development

  • Aligned Optum Financial Services with OptumInsight to integrate revenue cycle, payments, and financing for real-time healthcare transactions
  • Exited assets/geographies misaligned with U.S. value-based care focus; exiting one Medicaid state
  • OptumRx implemented new transparent pricing models and cost-based pharmacy reimbursement; removed prior auth on 180 drugs; moving to 100% rebate pass-through by 2027 (95% of customers in 2026)
  • Consolidated provider EMRs from 18 to 3 strategic systems across employee provider groups
  • New leadership at Optum driving operational improvements and execution discipline

Financials

  • 2025 adjusted EPS: $16.35
  • 2025 net of tax charge: $1.6B (~$1.78/share), largely non-cash
  • 2025 revenue: nearly $448B
  • 2025 medical care ratio (MCR): 89.1% (includes ~20 bps negative charge impact)
  • 2025 operating cost ratio (OCR): 13.3% (includes ~40 bps charge impact; ~+$800M for employee incentives and UnitedHealth Foundation funding)
  • 2025 operating cash flow: $19.7B (~1.5x net income)
  • 2026 guidance: revenue ~ $440B; adjusted EPS >$17.75; GAAP EPS β‰₯$17.10; earnings weighted slightly under two-thirds in 1H
  • Charge components: ~$800M cyber-related collections true-up; ~$440M net gain from portfolio optimization; ~$2.5B restructuring (incl. $625M lost contract reserve), real estate rationalization, workforce reductions

Capital & Funding

  • Strong 2025 operating cash flow of $19.7B supports investments and restructuring
  • Funded broad-based employee incentives and UnitedHealth Foundation (~$800M) in 2025
  • OptumRx transitioning to 100% rebate pass-through (95% in 2026; full by 2027)
  • Voluntary pledge to rebate ACA market profits to customers in 2026 to address affordability

Operations & Strategy

  • Repriced and rightsized UHC insurance businesses to prioritize sustainable, margin-accretive membership
  • AI-driven efficiency program targeting nearly $1B operating cost reductions in 2026; >80% of member calls aided by AI
  • OptumHealth narrowed affiliated network ~20% and streamlined risk membership ~15%; dropped unaligned PPO contracts and reduced ancillary services risk
  • Back-to-basics focus on integrated value-based care in markets with strong presence and wraparound services
  • OptumInsight prioritizing AI-first product innovation, cost discipline, and commercialization; tighter execution across Optum
  • Seasonal earnings cadence expected to be similar to 2025 with heavier 1H contribution

Market & Outlook

  • UHC total membership expected to contract by 2.3M–2.8M in 2026
  • Medicare Advantage membership expected to decline by 1.3M–1.4M in 2026; margins targeted to improve ~50 bps y/y
  • Medicaid membership expected to decline ~565k–715k (incl. DSNP) due to eligibility reductions and one-state exit
  • Commercial fully insured and ACA enrollment to contract; partially offset by growth in group self-funded offerings
  • Medicare medical cost trend ~7.5% in 2025; planning for ~10% in 2026 amid elevated utilization and higher service intensity
  • 2026 outlook tempered by third consecutive year of Medicare funding reductions, Medicaid shortfalls, and rising medical cost trends
  • Company engaging CMS on 2027 Advance Notice, which management says does not reflect current utilization/costs
  • Optum expects improving momentum in 2H26 carrying into 2027; UHC improvements more evident in 2026

Risks Or Headwinds

  • Medicare funding reductions and potential adverse 2027 rate setting
  • State Medicaid rate-acuity mismatches and ongoing funding shortfalls
  • Elevated medical utilization and higher service intensity driving Medicare trend to ~10%
  • Competitive Medicare Advantage environment causing higher plan shopping and membership losses
  • ACA market affordability challenges and regulatory uncertainty
  • Residual impacts from prior cyber-attack and structurally unprofitable contracts (lost contract reserve)
  • Revenue expected to decline in 2026 due to membership contraction and portfolio rationalization

Sentiment: CAUTIOUS

Note: This summary was synthesized by AI from the UNH Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
πŸ“

SEC Filings (UNH)

Β© 2026 Stock Market Info β€” UnitedHealth Group Incorporated (UNH) Financial Profile